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Genetically Determined Uric Acid and the Risk of Cardiovascular and
Neurovascular Diseases: A Mendelian Randomization Study of
Outcomes Investigated in Randomized Trials
Anthoula Efstathiadou, MD, MSc;* Dipender Gill, MD;* Frances McGrane, MD; Terence Quinn, MD, PhD;† Jesse Dawson, MD, PhD†
Background-—Higher serum uric acid levels are associated with cardiovascular and neurovascular disease, but whether these
relationships are causal is not known. We applied Mendelian randomization approaches to assess the association between
genetically determined uric acid levels and outcomes under study in large clinical trials.
Methods and Results-—We used 28 genetic variants related to serum uric acid as instruments to perform a range of 2-sample
Mendelian randomization methods. Our analysis had statistical power to detect clinically relevant effects of genetically determined
serum uric acid levels on the considered clinical outcomes; cognitive function, Alzheimer disease, coronary heart disease,
myocardial infarction, systolic blood pressure, and stroke. There was some suggestive evidence for an association between higher
genetically determined serum uric acid and cognitive function. There was also some suggestive evidence of a relationship between
coronary heart disease, systolic blood pressure, and the serum uric acid genetic instruments, but likely related to genetic
pleiotropy. Overall, there was no consistent evidence of a clinically relevant effect of genetically determined serum uric acid on any
of the considered outcomes.
Conclusions-—This Mendelian randomization study does not support a clinically relevant causal effect of genetically determined
serum urate on a range of cardiovascular and neurovascular outcomes. The weak association of genetically determined serum
urate with coronary heart disease and systolic blood pressure may be because of pleiotropic effects. If urate lowering drugs such
as allopurinol are found to affect these outcomes in clinical trials, then the effects may be mediated through urate independent
mechanisms. ( J Am Heart Assoc. 2019;8:e012738. DOI: 10.1161/JAHA.119.012738.)
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O bservational studies have shown a relationship betweenhigher serum uric acid levels and increased risk of stroke, coronary heart disease (CHD), total cardiovascularevents and incident hypertension.1–4 There may also be a
complicated relationship with dementia—hyperuricemia may
accelerate cerebrovascular disease resulting in vascular
dementia,5 but may be neuroprotective in Alzheimer or
Parkinson dementia, because of its antioxidant properties.6
However, causality has not been confirmed and there is
considerable potential for confounding. The Mendelian ran-
domization (MR) approach can overcome some of the
limitations of observational studies such as confounding or
reverse causation to make causal inferences.7 MR uses
genetic variants randomly allocated at conception that are not
associated with environmental confounders, such as single-
nucleotide polymorphisms (SNPs), as instruments to study the
effect of varying an exposure on risk of a particular outcome.7
SNPs associated with uric acid can therefore be used as
proxies for phenotypic serum uric acid levels to produce valid
causal estimates when the underlying requisite assumptions
of MR are met.8
Horizontal pleiotropy represents a violation of the requisite
MR assumptions and occurs when the instruments are
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associated directly with the outcome independently of the
exposure.9 MR analyses studying the effects of uric acid on
cardiovascular disease and hypertension have previously been
performed, with some supporting a causal association.10–12 In
addition, a recent MR study did not find an association
between serum uric acid levels and Alzheimer disease risk,
but other dementia types or cognitive function were not
investigated.13 Similarly, to our knowledge there is no
published MR investigation of the role of uric acid on
ischemic stroke and its subtypes.
Clinical trials of allopurinol, the most widely used uric acid
lowering drug, are underway in the setting of cardiovascular
disease and are exploring effects on blood pressure, cardio-
vascular event rate in patients with CHD (ALL-HEART)14 and
on cognitive and cardiovascular outcomes in patients with
stroke (XILO-FIST [Xanthine oxidase inhibition for improve-
ment of long-term outcomes following ischaemic stroke and
transient ischaemic attack]).15 Numerous other small studies
are in progress exploring surrogate outcomes. Allopurinol
lowers serum uric acid in a dose dependent fashion, but also
reduces the formation of reactive oxygen species and some of
its vascular effects may be independent of uric acid reduc-
tion.16 These clinical trials will help inform on whether
allopurinol improves outcomes, although interpretation of the
mechanism of any improvement will be limited.
In this study, we performed MR analyses investigating the
relationship between genetically determined serum uric acid
levels and the range of cardiovascular and associated
outcomes under study in trials (cognitive performance,
Alzheimer disease, CHD, myocardial infarction [MI], systolic
blood pressure [SBP], ischemic stroke and its subtypes [large-
artery atherosclerotic stroke {LAS}, cardioembolic stroke,
and stroke caused by small-vessel disease {SVS}]). Methods
for dealing with potential violations of the modelling assump-
tions were incorporated, including a range of statistical
sensitivity analyses performed to investigate the robustness
of the findings.
Methods
All data used in this study come from GWAS (genome-wide
association study) meta-analyses for which ethical approval
and patient consent were previously obtained. The data used
are available upon reasonable request from the corresponding
author.
Genetic Association Estimates
We used 28 SNPs associated with serum uric acid concen-
tration at genome-wide significance (P<59108) as genetic
instruments. These were identified from a GWAS meta-
analysis of 110 347 participants of European ancestry.17 All
28 SNPs were replicated, and overall explained 5.8% of the
variability in uric acid levels. In the largest study of the GWAS
meta-analysis, the mean uric acid concentration was 6.0 mg/
dL and the standard deviation (SD) was 1.5 mg/dL. The
strength of each instrument was evaluated using F-statistic
values, which were in turn calculated based on R2, the
proportion of phenotypic variance explained by each SNP.18,19
Genetic association estimates of SNP-outcome relation-
ships were extracted from different data sets. For cognitive
ability, SNPs were derived from a GWAS meta-analysis
performed by the UK Biobank and Cognition Genomics
Consortium (COGENT) on 257 841 participants of European
origin.20 Cognitive function was measured using a test of
verbal-numerical reasoning in the UK Biobank, and neuropsy-
chological assessments in COGENT study, further details for
which are available in the original reporting studies.21,22
Cognitive performance was standardized (mean=0 and SD=1).
Genetic association estimates for Alzheimer disease were
extracted from the discovery stage of the International
Genomics of Alzheimer’s Project (IGAP), a meta-analysis of
4 GWASs with a total of 17 008 cases and 37 154 controls,
all of European ancestry.23 The Coronary Artery Disease
Genome Wide Replication and Meta-Analysis (CARDIoGRAM)
plus The Coronary Artery Disease (C4D) (CARDIoGRAM-
plusC4D) 1000 Genomes-based GWAS meta-analysis was
used to derive the association estimates for CHD and MI.24
There were 60 801 CHD cases and 123 504 controls, with
Clinical Perspective
What Is New?
• It is not known whether there is an association between
serum uric acid and various cardiovascular and neurovas-
cular outcomes.
• Mendelian randomization is a statistical approach that uses
genetic variants such as single-nucleotide polymorphisms
as genetic instruments to make causal inferences on the
nature of an exposure-outcome relationship.
• This study used the Mendelian randomization technique to
investigate the effect of genetically determined uric acid
levels on cardiovascular and neurovascular outcomes under
investigation in clinical trials.
What Are the Clinical Implications?
• We did not find evidence of any clinically relevant causal
association between uric acid and coronary heart disease,
myocardial infarction, systolic blood pressure, cognitive
function, Alzheimer disease or any type of ischemic stroke.
• The protective role of urate lowering drugs on cardiovascu-
lar disease suggested by many observational studies and
clinical trials might be attributable to urate independent
mechanisms.
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the majority of participants (77%) being of European ancestry.
The CHD definition included MI (70% of the total number of
cases), acute coronary syndrome and angina pectoris. For
SBP, data on 473 891 European-ancestry participants from
the UK Biobank were used, with SBP estimates obtained from
automated readings at baseline assessment, and having a
mean value of 137.82 and an SD of 19.3 in the considered
population.25 Finally, for ischemic stroke and its subtypes
LAS, cardioembolic stroke, and SVS, genetic association
estimates were derived from a multi-ancestry GWAS per-
formed by the MEGASTROKE Consortium, on 60 341 cases of
any type of ischemic stroke (6688 of LAS; 9006 of
cardioembolic stroke; 11 710 of SVS) and 454 450 con-
trols.26 Table 1 contains the information for all the data sets
used in this study.
Mendelian Randomization Power Calculation
Information on the available sample size and the percentage
of phenotypic variance explained by the instruments was used
to perform power calculations for conventional MR analyses
using the mRnd power calculator (available at http://
cnsgenomics.com/shiny/mRnd/).27 The smallest effect of
uric acid (on all outcomes separately) required to achieve at
least 80% statistical power given the sample size and
percentage of phenotypic variance explained was calculated
for the main analysis.
Mendelian Randomization Analyses and
Investigation of Pleiotropy
For inverse-variance weighted (IVW) ratio method MR, we
generated MR estimates for each SNP using the Wald
estimator (ratio of SNP-outcome estimate over SNP-exposure
estimate), with standard errors calculated using the Delta
method to account for possible measurement error in both
the exposure and outcome association estimates.28,29 In the
main analysis, the final effect estimate for each outcome was
derived by pooling all MR estimates using the fixed-effects
IVW method.30 As this method assumes the absence of any
horizontal pleiotropic effects of the genetic instruments on
the considered outcome through pathways independent of the
exposure (which in this case is serum uric acid) and is
vulnerable to bias if this assumption does not hold, further MR
methods that have less stringent assumptions on horizontal
pleiotropy were therefore performed in sensitivity analyses.
We estimated the intercept and slope of MR-Egger regression,
which represent the average horizontal pleiotropy and a
pleiotropy-adjusted MR estimate, respectively.31 An intercept
value for this regression that does not include the null
(P<0.05) was considered indicative of horizontal pleiotropy.31
MR-Egger makes the assumption that the strength of the
instruments is not correlated to any pleiotropic effect that
they have.31 Additionally, the weighted median estimator was
performed.32 This is the weighted median effect of all the MR
estimates produced by individual instruments, with weights
equal to the inverse of the standard error.32 It is valid when
more than half the information from the analysis comes from
valid instruments.32 Finally, the Mendelian Randomization
Pleiotropy Residual Sum and Outlier (MR-PRESSO) method
was performed, which excludes outliers determined by the
square of residual errors from the SNP-outcome against SNP-
exposure regression to calculate an outlier-free effect
estimate.33
Increased body mass index (BMI) has been causally
associated with higher levels of serum uric acid in a recent
MR study by Palmer et al.11 To reduce any possible genetic
confounding related to associations of the uric acid instru-
ments with BMI, we adjusted for this using conventional
regression-based multivariable MR.34 Multivariable MR is a
linear regression-based method with >1 explanatory vari-
able.34 The genetic association estimates for BMI were
derived from a GWAS meta-analysis of the Genetic Investiga-
tion of Anthropometric Traits (GIANT) Consortium and UK
Biobank, including 700 000 European-ancestry partici-
pants.35
An additional sensitivity analysis to deal with any potential
horizontal pleiotropy was performed. We examined whether
the 28 SNPs were associated with any traits other than uric
acid levels, using the PhenoScanner online data set of publicly
available GWAS results (http://www.phenoscanner.medsc
hl.cam.ac.uk/phenoscanner, accessed February 1, 2019),
identifying associations that were genome-wide significant
(P<59108), and also considering proxy SNPs (linkage
disequilibrium r2>0.8).36 The whole analysis was then
repeated using only the SNPs that were exclusively associated
with uric acid and/or gout. For the considered 9 outcomes,
we accounted for multiple testing in the main analysis using a
Bonferroni correction.
We used R software (version 3.5.1) and the MendelianRan-
domization37 and MRPRESSO33 software packages to perform
analyses.
Results
All 28 SNPs had F-statistic values >10, suggesting that they
were unlikely to introduce marked weak instrument bias into
the MR analyses.18 Table S1 contains the individual associ-
ation estimates for uric acid and F-statistic values of each
instrument SNP. Investigating potentially pleiotropic associa-
tions identified that only 7 out of the 28 instrument SNPs
were exclusively associated with either uric acid levels and/or
gout (Table S2). Power calculations for the conventional IVW
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MR analyses using the 28 SNPs indicated >80% statistical
power to detect an odds ratio (OR) <0.97 or >1.04 per 1 mg/
dL increase in uric acid for the urate-CHD/MI relationships
and a beta estimate smaller or >0.096 per 1 mg/dL increase
in uric acid for the urate-SBP relationship. Similar power
calculations were found for the MR analysis using the 7 SNPs
specific to urate/gout. Tables S3 and S4 contain the power
calculations for all outcomes for the 28 SNPs and 7 SNPs
analyses, respectively. All results in this study are reported
per 1 mg/dL increase in genetically determined uric acid.
Cognition and Alzheimer Disease
The results for uric acid and cognition are shown in Table 2.
All analyses found an inverse relationship between serum uric
acid level and cognitive performance. However, only the effect
estimates from the weighted median method had a significant
effect after adjusting for multiple testing using the Bonferroni
correction (P<0.005) (weighted median estimate for the 7
only-urate associated SNPs: b 0.03; 95% CI 0.05–0.01;
P=3.7791004).38 The intercept of the MR-Egger regression
did not suggest the presence of directional pleiotropy
(P=0.72). Results were consistent between all 28 and 7 SNPs.
Regarding Alzheimer disease, there was no demonstrable
relationship with uric acid in any analysis (IVW method for the
7 SNPs analysis: OR 1.05; 95% CI 0.93–1.17; P=0.48). In
addition, no horizontal pleiotropy was suggested by the MR-
Egger test (P=0.13). Detailed results can be found in Table 2.
Coronary Heart Disease and Myocardial
Infarction
There was an apparent effect of uric acid on CHD in outlier-
corrected MR-PRESSO (OR 1.07; 95% CI 1.03–1.12;
P=2.999103), but not in any other method or in analyses
restricted to the 7 SNPs specific for urate (Table 3). The MR-
Table 2. Results From All MR Analyses for the Association of Uric Acid With Cognitive Performance and Alzheimer Disease
Uric Acid on Cognition b (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 0.02 (0.04–0.01) 0.16
Weighted median 0.03 (0.05–0.01) 1.0091003
MR-Egger 0.02 (0.06–0.01) 0.22
MR-PRESSO (outliers corrected; 3 outliers) 0.02 (0.04–0.01) 0.02
MR-PRESSO (raw) 0.02 (0.04–0.01) 0.17
MVMR adjusting for BMI 0.02 (0.04–0.01) 0.19
Analysis with 7 SNPs*
Fixed-effects IVW 0.03 (0.06–0.00) 0.08
Weighted median 0.03 (0.05–0.01) 3.7791004
MR-Egger 0.03 (0.07–0.02) 0.27
MR-PRESSO (raw; 0 outliers) 0.03 (0.07–0.00) 0.09
Uric Acid on Alzheimer OR (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 1.03 (0.96–1.10) 0.47
Weighted median 1.04 (0.95–1.14) 0.42
MR-Egger 1.08 (0.98–1.20) 0.12
MR-PRESSO (raw; 0 outliers) 1.03 (0.96–1.10) 0.49
MVMR adjusting for BMI 1.03 (0.96–1.11) 0.35
Analysis with 7 SNPs*
Fixed-effects IVW 1.05 (0.93–1.17) 0.48
Weighted median 1.05 (0.95–1.15) 0.31
MR-Egger 1.06 (0.90–1.25) 0.48
MR-PRESSO (raw; 0 outliers) 1.04 (0.93–1.17) 0.49
BMI indicates body mass index; IVW, inverse variance weighted; MR-PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; MR, Mendelian randomization; MVMR,
multivariable Mendelian randomization analysis; SNP, single-nucleotide polymorphisms.
*The 7 non-pleiotropic SNPs that are associated with only uric acid or/and gout.
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Egger test did not provide evidence of horizontal pleiotropy
(P=0.06). Similar results were found for MI (Table 3).
Systolic Blood Pressure
In the main analysis using the 28 SNPs, 1 mg/dL increase in
uric acidwas associatedwith 0.47 mm Hg increase in SBP (IVW
method: 95% CI 0.02–0.95; P=0.07). There was a suggestive
association when performing the outlier corrected MR-PRESSO
method with all 28 SNPs, but this was not statistically
significant after Bonferroni correction (MR-PRESSO method; b
0.58; 95% CI 0.19–0.97; P=0.01) (Table 3). In addition, the MR-
Egger test suggested the presence of horizontal pleiotropy
when considering all 28 SNPs (P=29103).
Stroke
The effect estimates for ischemic stroke and its subtypes
were consistent throughout all analysis methods and were not
suggestive of an association between uric acid and ischemic
stroke or its subtypes (Table 4). The OR for the effect of
genetically determined uric acid on any type of ischemic
stroke when using the IVW method in the 28 SNPs analysis
was 1.00 (95% CI 0.94–1.06; P=0.99) and was consistent
after adjusting for BMI in multivariable Mendelian randomiza-
tion (OR 0.99; 95% CI 0.92–1.07; P=0.89) or after using the 7
SNPs associated with only uric acid/gout (IVW: OR 0.96; 95%
CI 0.91–1.02; P=0.20). The MR-Egger intercepts of all stroke
analyses were found to be close to 0, indicating the absence
of horizontal pleiotropy.
The association estimates of the SNPs with cognitive
performance, Alzheimer disease, CHD, MI, SBP, and ischemic
stroke and its subtypes are presented in Tables S5 through S13,
respectively. Figures S1 through S9 are Forest plots represent-
ing the individual SNP MR estimates of the 28 SNPs for all
outcomes, respectively. Funnel and Radial plots to visualize the
presence of heterogeneity for every outcome are provided in
Figures S10 through S18. Forest plots containing the associ-
ation estimates found using each method for the uric acid-
Table 3. Results From All MR Analyses for the Association of
Uric Acid With Coronary Heart Disease, Myocardial Infarction,
and Systolic Blood Pressure
Uric Acid on CHD OR (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 1.08 (1.02–1.14) 0.01
Weighted median 1.05 (0.99–1.11) 0.10
MR-Egger 1.02 (0.94–1.12) 0.63
MR-PRESSO (outlier
corrected; 1 outlier)
1.07 (1.03–1.12) 2.9991003
MR-PRESSO (raw) 1.08 (1.02–1.16) 0.02
MVMR adjusting for BMI 1.07 (1.01–1.14) 0.04
Analysis with 7 SNPs*
Fixed-effects IVW 1.04 (0.97–1.11) 0.29
Weighted median 1.03 (0.97–1.09) 0.29
MR-Egger 1.03 (0.95–1.11) 0.58
MR-PRESSO
(raw; 0 outliers)
1.04 (0.97–1.11) 0.29
Uric Acid on MI OR (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 1.09 (1.02–1.16) 0.02
Weighted median 1.06 (0.99–1.12) 0.08
MR-Egger 1.01 (0.92–1.12) 0.80
MR-PRESSO (outlier
corrected; 1 outlier)
1.08 (1.03–1.14) 4.4191003
MR-PRESSO (raw) 1.10 (1.01–1.18) 0.03
MVMR adjusting
for BMI
1.08 (1.00–1.17) 0.05
Analysis with 7 SNPs*
Fixed-effects IVW 1.04 (0.97–1.12) 0.28
Weighted median 1.04 (0.98–1.11) 0.22
MR-Egger 1.03 (0.93–1.14) 0.54
MR-PRESSO (raw; 0
outliers)
1.04 (0.97–1.12) 0.28
Uric Acid on SBP b (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 0.47 (0.02 to 0.95) 0.07
Weighted median 0.23 (0.07 to 0.53) 0.13
MR-Egger 0.25 (0.97 to 0.47) 0.49
MR-PRESSO (outlier
corrected; 4 outliers)
0.58 (0.19–0.97) 0.01
MR-PRESSO (raw) 0.57 (0.02 to 1.16) 0.07
MVMR adjusting for BMI 0.56 (0.05 to 1.17) 0.08
Analysis with 7 SNPs*
Fixed-effects IVW 0.34 (0.18 to 0.86) 0.25
Continued
Table 3. Continued
Uric Acid on SBP b (95% CI) P Value
Weighted median 0.21 (0.09 to 0.51) 0.15
MR-Egger 0.12 (0.53 to 0.30) 0.59
MR-PRESSO (outliers
corrected; 1 outlier)
0.31 (0.19 to 0.80) 0.28
MR-PRESSO (raw) 0.36 (0.19 to 0.90) 0.25
BMI indicates body mass index; CHD, coronary heart disease; IVW, inverse variance
weighted; MR-PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier;
MI, myocardial infarction; MR, Mendelian randomization; MVMR, multivariable Mendelian
randomization analysis; SBP, systolic blood pressure.
*The 7 non-pleiotropic SNPs that are associated with only uric acid or/and gout.
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cognition and uric acid-Alzheimer disease analyses are provided
in Figures S19 and S20, respectively. Similarly, Figure S21 is a
Forest plot of the uric acid-CHD and uric acid-MI relationships,
with Figures S22 and S23 the same for uric acid-SBP and uric
acid-ischemic stroke and its subtypes, respectively.
Discussion
Our study did not provide consistent MR evidence to support
a causal effect of genetically determined serum uric acid
levels on cognitive function, Alzheimer disease, CHD, MI, or
ischemic stroke, including its subtypes (cardioembolic stroke,
SVS, and LAS), despite the associations observed in many
observational studies.1–5 Although there was some evidence
for an association with cognitive function, coronary outcomes
and SBP, the findings did not survive correction for multiple
testing and sensitivity analyses investigating bias related to
pleiotropy. Although the analysis with 7 instrument SNPs had
lower statistical power than that with 28 SNPs, it is important
to appreciate that all the IVW MR analyses had sufficient
power to detect clinically meaningful associations. These
results will therefore help interpret results from ongoing
clinical trials and inform the direction of future study.
Our results were suggestive of an inverse association
between uric acid and cognitive performance, as the effect
estimates of this relationship were consistent throughout all
analysis methods and approached statistical significance, even
after accounting for multiple testing. Whether this effect is of
clinical importance, however, needs to be clarified and more
Table 4. Results From All MR Analyses for the Association of
Uric Acid With Ischemic Stroke and its Subtypes
Uric Acid on Ischemic Stroke OR (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 1.00 (0.94–1.06) 0.99
Weighted median 0.98 (0.93–1.03) 0.42
MR-Egger 0.95 (0.85–1.05) 0.31
MR-PRESSO
(outlier corrected; 1 outlier)
1.00 (0.95–1.05) 0.87
MR-PRESSO (raw) 1.00 (0.94–1.08) 0.86
MVMR adjusting for BMI 0.99 (0.92–1.07) 0.89
Analysis with 7 SNPs*
Fixed-effects IVW 0.96 (0.91–1.02) 0.20
Weighted median 0.97 (0.92–1.03) 0.33
MR-Egger 0.99 (0.93–1.06) 0.82
MR-PRESSO
(raw; 0 outliers)
0.96 (0.91–1.02) 0.20
Uric Acid on CES OR (95% CI) P Value
Analysis with 28 SNP
Fixed-effects IVW 0.97 (0.89–1.05) 0.44
Weighted median 0.95 (0.86–1.05) 0.32
MR-Egger 0.92 (0.82–1.04) 0.20
MR-PRESSO (raw; 0 outliers) 0.97 (0.89–1.06) 0.49
MVMR adjusting for BMI 0.97 (0.89–1.06) 0.50
Analysis with 7 SNPs*
Fixed-effects IVW 0.93 (0.87–1.00) 0.08
Weighted median 0.95 (0.85–1.06) 0.33
MR-Egger 0.97 (0.85–1.10) 0.60
MR-PRESSO (raw; 0 outliers) 0.93 (0.87–1.00) 0.08
LAS OR (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 1.01 (0.88–1.15) 0.94
Weighted median 0.94 (0.83–1.07) 0.36
MR-Egger 0.89 (0.74–1.08) 0.24
MR-PRESSO
(outliers corrected;
1 outlier)
1.00 (0.88–1.13) 0.98
MR-PRESSO (raw) 1.01 (0.88–1.16) 0.87
MVMR adjusting for BMI 1.00 (0.86–1.15) 0.98
Analysis with 7 SNPs*
Fixed-effects IVW 0.92 (0.84–1.01) 0.13
Weighted median 0.93 (0.81–1.06) 0.27
MR-Egger 0.93 (0.79–1.10) 0.41
MR-PRESSO (raw; 0 outliers) 0.92 (0.84–1.01) 0.13
Continued
Table 4. Continued
SVS OR (95% CI) P Value
Analysis with 28 SNPs
Fixed-effects IVW 1.04 (0.92–1.16) 0.55
Weighted median 1.05 (0.94–1.17) 0.41
MR-Egger 1.08 (0.90–1.28) 0.42
MR-PRESSO (outliers
corrected; 1 outlier)
1.03 (0.93–1.13) 0.62
MR-PRESSO (raw) 1.04 (0.92–1.17) 0.54
MVMR adjusting for BMI 1.02 (0.90–1.15) 0.79
Analysis with 7 SNPs*
Fixed-effects IVW 1.02 (0.93–1.12) 0.71
Weighted median 1.04 (0.92–1.17) 0.56
MR-Egger 1.09 (0.94–1.26) 0.27
MR-PRESSO (raw; 0 outliers) 1.02 (0.93–1.12) 0.72
BMI indicates body mass index; CES, cardioembolic stroke; IVW, inverse variance
weighted; LAS, large-artery atherosclerotic stroke; MR, Mendelian randomization; MR-
PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; MVMR,
multivariable Mendelian randomization analysis; SVS, small-vessel stroke.
*The 7 non-pleiotropic SNPs that are associated with only uric acid or/and gout.
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research is needed. We also need to acknowledge that this
study does not exclude the presence of smaller effects, or
effects of allopurinol lowering drugs distinct from the effect of
general urate lowering. Any relationship between uric acid
levels and cognitive function or dementia is likely to be complex
given the heterogeneous nature of dementias, the antioxidant
effects of uric acid and the detrimental effects of chronic
hyperuricemia on the vasculature. Observational studies
suggest the relationship may differ by dementia subtype. In a
recent systematic review and meta-analysis, serum uric acid
levels were lower in people with Alzheimer disease and
dementia associated with Parkinson disease but there was
no association with vascular dementia.39 Experimental studies
suggest a neuroprotective effect of uric acid which may be
beneficial in some neurodegenerative disorders,6 but also that
chronic hyperuricemia could induce cognitive impairment via
vascular damage.5 Our data support this. Studies assessing the
relationship between instrumental variables for uric acid and
vascular dementia would be helpful.
Considering the other outcomes, while for CHD and SBP
there was some evidence of an association, the importance and
clinical relevance of this is debatable. Our analysis for SBP
suggested that 1 mg/dL increase in genetically determined
uric acid would increase blood pressure by 0.34 mm Hg (IVW
for the 7 SNPs analysis: 95% CI 0.18–0.86; P=0.25).
However, other MR studies do support a causal role for
hyperuricemia in hypertension10,12 (although there are discor-
dant reports11,40) and clinical trials suggest a larger effect. A
clinical trial of uric acid lowering therapies in adolescents
showed an 10 mm Hg fall in SBP with both allopurinol and
probenecid.41,42 If a fall of this magnitude was present in older
adults, it would be associated with a 41% reduction in stroke
events and a 22% reduction in CHD events.41,42 Whether these
changes exist in older adults at risk of cardiovascular disease
now needs to be established in clinical trials. The presence of a
small effect in an MR study in the predominantly “healthy” UK
Biobank population does not exclude a similar larger and
important effect of uric acid reduction in hyperuricemia adults
at increased risk. Further clinical trials are needed to assess
this. The fact that both a xanthine oxidase inhibitor and a
uricosuric drug lowered blood pressure in adolescents raises
the possibility that this effect is mediated by uric acid itself and
not by xanthine oxidase inhibition or a reduction in oxidative
stress. However, there are alternative explanations. The effects
of xanthine oxidase inhibitors may be uric acid independent;
high doses of allopurinol, but not probenecid, improved
measures of endothelial function in adults with heart failure
and it is of interest that trials of uric acid reduction have been
neutral in this setting.43,44 Further, probenecid may exert its
effects via changes in renal function and MR studies have
suggested that activity of uric acid transporters rather than the
level of uric acid itself is related to renal function.45 Whether
the observed effects of probenecid on renal function are
because of this mechanism or a uric acid effect is unclear.
Further clinical study should aim to establish this.
MR studies have also shown an association between uric
acid and CHD10,12 but again there are conflicting reports.40
Hypertension is the biggest risk factor for stroke and if
hyperuricemia causes this, a downstream effect on the risk of
stroke would be expected. Stroke is a heterogeneous
condition and the presence of an association with CHD
makes it attractive to hypothesize there would be an
association with LAS, which overlap in its etiology.26 However,
we saw no MR evidence of this.
The findings of this study will help plan and interpret
results of clinical trials of uric acid reduction. Both allopurinol
and probenecid have been shown to reduce blood pressure in
adolescents by between 6 and 10 mm Hg systolic.41,42
Allopurinol has also been shown to reduce left ventricular
hypertrophy and carotid intima media thickness.43,46,47 Left
ventricular hypertrophy is a key risk factor for stroke and the
lack of association with stroke (and LAS in particular in our
study) raises the possibility that these effects are mediated by
xanthine oxidase and not uric acid. Our data do not exclude
potentially beneficial effects of allopurinol that are mediated
via uric acid independent mechanism. Indeed, if clinical trials
of allopurinol yield benefit on outcomes such as stroke, we
could infer these effects are uric acid independent. Further-
more, patients with stroke have a higher risk of cognitive
impairment and cardiac disease so a potentially beneficial
effect of uric acid reduction in this population cannot be
excluded. Overall however, we feel our data suggest trials of
uric acid reduction in the setting of cardiovascular disease
should focus on cardiac end points or blood pressure
reduction. It is likely that if clinically important effects are
seen that they will at least in part be because of urate
independent mechanisms. Further, the potential for genetic
information to identify people with particularly harmful forms
of hyperuricemia, or who are most likely to respond to uric
acid reduction, should be considered. This could be done by
analysis of genetic data in ongoing trials.
Strengths of our study include the large sample size for
each MR analysis with good statistical power. Both the 28 and
7 SNPs analyses had sufficient power to detect clinically
relevant effect estimates (Tables S3 and S4). The availability
of large-scale GWASs for a range of relevant neurological and
vascular outcomes further allowed investigation across the
relevant outcome phenotypes in a manner more efficient that
afforded by clinical trial,48 and also overcoming the issues of
confounding and reverse causation bias that can limit
traditional observational research.49 Furthermore, robust
methods were applied to deal with possible violations of the
requisite assumptions of MR, including horizontal
pleiotropy.50
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Limitations of this work include the fact that the sample size
for subtypes of stroke was smaller than for other analyses,
having potential implications for fine-mapping the effects of
uric acid on stroke subtypes that vary in their underlying
etiology and pathophysiology.26 Furthermore, it is important to
appreciate that MR measures the cumulative effect of lifelong
exposure to genetic variants related to serum uric acid levels,
and that this is not the same as studying the effect of a discrete
clinical intervention in adult life.51 These MR results should
therefore not be extrapolated to assume the effect of clinical
intervention on uric acid levels, particularly as the MR approach
may be subject to some residual bias related to pleiotropy
despite the pleiotropy robust approaches. Furthermore, ther-
apies for uric acid reduction may be having effects on
neurological and vascular disease partly unrelated to their
effects on uric acid.43–47 Finally, because of the fact that there
is no available power calculation technique for MR-Egger, we
were not able to provide statistical power calculations for this
analysis. Therefore, our analysis could contain false negative
results on the MR-Egger test for directional pleiotropy.
Conclusions
In conclusion, our study did not provide consistent evidence
to support that genetically determined serum uric acid has a
clinically relevant causal effect on risk of the considered
cardiovascular and neurovascular outcomes. If there is an
effect of urate lowering drugs on these mechanisms, it may be
mediated by urate independent mechanisms.
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Table S1. All 28 SNPs for serum urate from Köttgen et al study (1) 
 
  
SNP chr EA OA EAF GX SE_GX pval N MAF R2 F-statistic 
1 rs10480300  7 T C 0.280 0.035 0.006 4.10E-09 110,347 0.28 0.00030828 34.016363 
2 rs10821905  10 A G 0.180 0.057 0.007 7.40E-17 110,347 0.18 0.00060053 66.2645023 
3 rs11264341  1 T C 0.430 -0.050 0.006 6.20E-19 110,347 0.43 0.00062893 69.3988818 
4 rs1165151  6 T G 0.470 -0.091 0.005 7.00E-70 110,347 0.47 0.00299282 330.23968 
5 rs1171614  10 T C 0.220 -0.079 0.007 2.30E-28 110,347 0.22 0.00115291 127.217045 
6 rs1178977  7 A G 0.810 0.047 0.007 1.20E-12 110,347 0.19 0.00040838 45.0619972 
7 rs12498742  4 A G 0.770 0.373 0.006 1.00E-10 110,347 0.23 0.03383799 3733.81943 
8 rs1260326  2 T C 0.410 0.074 0.005 1.20E-44 110,347 0.41 0.00198108 218.600121 
9 rs1394125  15 A G 0.340 0.043 0.006 2.50E-13 110,347 0.34 0.00046523 51.3358205 
10 rs1471633  1 A C 0.460 0.059 0.005 1.20E-29 110,347 0.46 0.00126025 139.060742 
11 rs17050272  2 A G 0.430 0.035 0.006 1.60E-10 110,347 0.43 0.00030828 34.016363 
12 rs17632159  5 C G 0.310 -0.039 0.006 3.50E-11 110,347 0.31 0.00038274 42.2326812 
13 rs17786744  8 A G 0.580 -0.029 0.005 1.4E-08 110,347 0.42 0.00030476 33.6288335 
14 rs2078267  11 T C 0.510 -0.073 0.006 9.40E-38 110,347 0.49 0.00133968 147.825449 
15 rs2231142  4 T G 0.110 0.217 0.009 1.00E-134 110,347 0.11 0.00524073 578.28328 
16 rs2941484  8 T C 0.440 0.044 0.005 4.40E-17 110,347 0.44 0.00070129 77.3835879 
17 rs3741414  12 T C 0.240 -0.072 0.007 2.20E-25 110,347 0.24 0.00095784 105.69171 
18 rs478607  11 A G 0.840 -0.047 0.007 4.40E-11 110,347 0.16 0.00040838 45.0619972 
19 rs653178  12 T C 0.510 -0.035 0.005 7.20E-12 110,347 0.49 0.00044386 48.9769195 
20 rs6598541  15 A G 0.360 0.043 0.006 4.80E-15 110,347 0.36 0.00046523 51.3358205 
21 rs675209  6 T C 0.270 0.061 0.006 1.30E-23 110,347 0.27 0.00093582 103.261577 
22 rs6770152  3 T G 0.580 -0.044 0.005 2.60E-16 110,347 0.42 0.00070129 77.3835879 
23 rs7188445  16 A G 0.330 -0.032 0.005 1.60E-09 110,347 0.33 0.00037106 40.9436884 
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24 rs7193778  16 T C 0.860 -0.046 0.008 8.20E-10 110,347 0.14 0.00029953 33.0516981 
25 rs7224610  17 A C 0.580 -0.042 0.005 5.40E-17 110,347 0.42 0.00063903 70.512993 
26 rs729761  6 T G 0.300 -0.047 0.006 8.00E-16 110,347 0.3 0.00055577 61.3253415 
27 rs7953704 12 A G 0.470 -0.029 0.005 2.6E-08 110,347 0.47 0.00030476 33.6288335 
28 rs7976059  12 T G 0.350 0.032 0.005 1.90E-09 110,347 0.35 0.00037106 40.9436884 
 
 
SNP: each SNP's id;  chr: chromosome; EA: effect allele; OA: other allele; EAF: effect allele frequency for GX; GX: beta for the SNP-
urate relationship; SE_GX: standard error of GX; pval: p-value of GX; N: sample size of the study from which each SNP was found; 
MAF: minor allele frequency; R2: % of variance in cognition explained by each SNP, calculated by: R2=2*GX^2*MAF*(1-
MAF)/[2*GX^2*MAF*(1-MAF)+ SE_GX^2*2*N*MAF*(1-MAF)](2); F-statistic: a measurement of instrument's strength, calculated by: 
F-statistic=R2*(N-2)/1-R2 (3) 
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Table S2. The 7 SNPs that are only associated with serum urate or/and gout (1) after excluding the pleiotropic SNPs using 
Phenoscanner (4) 
 
  
SNP chr EA OA EAF GX SE_GX pval R2 F-statistic 
1 rs12498742 4 A G 0.77 0.373 0.006 1.00E-10 0.03383799 3733.81943 
 
2 rs1471633 1 A C 0.46 0.059 0.005 1.20E-29 0.00126025 
 
139.060742 
 
3 rs2078267 11 T C 0.51 -0.073 0.006 9.40E-38 0.00133968 
 
147.825449 
 
4 rs2941484 8 T C 0.44 0.044 0.005 4.40E-17 0.00070129 
 
77.3835879 
 
5 rs6770152 3 T G 0.58 -0.044 0.005 2.60E-16 0.00070129 
 
77.3835879 
 
6 rs7224610 17 A C 0.58 -0.042 0.005 5.40E-17 0.00063903 
 
70.512993 
 
7 rs7976059 12 T G 0.35 0.032 0.005 1.90E-09 0.00037106 
 
40.9436884 
 
 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele; OA: other allele; EAF: effect allele frequency for GX; GX: beta for the SNP-
urate relationship; SE_GX: standard error of GX; pval: p-value of GX 
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Table S3. Power calculations for all analyses using the 28 SNPs. The calculations were made using the mRnd power 
calculator (available at http://cnsgenomics.com/shiny/mRnd/)  (5)  
 
 
CHD 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
CARDIoGRAMplusC4D 1000 Genomes-based 
GWAS (6) 
Proportion of CAD 
cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.058 0.05 184,305 0.33 0.97 1.04 
MI 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
CARDIoGRAMplusC4D 1000 Genomes-based 
GWAS (6) 
Proportion of MI cases minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.058 0.05 184,305 0.23 0.96 1.04 
COGNITION 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; (Lee et al) 
(7) 
 
β OLS* 
 
σ2 (x)** 
 
  σ2 (y) 
*** 
minimum beta to have 
>80% power 
0.058 0.05 257,841 0 2.25 1 0.135 
SBP 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; SBP 
automated (UK biobank) (8) 
 
β OLS* 
 
σ2 (x)** 
 
  σ2 (y) 
*** 
minimum beta to have 
>80% power 
0.058 0.05 473,891 0 2.25 1 0.096 
ALZHEIMER 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; IGAP 1st 
stage (9) 
Proportion of 
Alzheimer cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.058 0.05 54,162 0.31 0.93 1.08 
STROKE 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
MEGASTROKE (10) 
Proportion of any 
ischemic stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
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0.058 0.05 514,791 0.12 0.97 1.03 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
METASTROKE (10) 
Proportion of CES 
stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.058 0.05 514,791 0.02 0.92 1.08 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
METASTROKE (10) 
Proportion of LAS 
stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.058 0.05 514,791 0.013 0.91 1.10 
% of variance in urate 
explained by the 28 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
METASTROKE (10) 
Proportion of SVS 
stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.058 0.05 514,791 0.023 0.92 1.07 
 
 
* the observational association estimate of the exposure-outcome relationship 
** variance of the exposure variable (x),  
*** variance of the outcome variable (y) 
CHD; coronary heart disease, MI; myocardial infraction, SBP; systolic blood pressure, CES; cardioembolic stroke, LAS; large vessels stroke, SVS; small vessels 
stroke 
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Table S4. Power calculations for all analyses using the 7 SNPs. The calculations were made using the mRnd power 
calculator (available at http://cnsgenomics.com/shiny/mRnd/)  (5) . 
 
 
CHD 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
CARDIoGRAMplusC4D 1000 Genomes-based 
GWAS (6) 
Proportion of CAD 
cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.039 0.05 184,305 0.33 0.95 1.05 
MI 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
CARDIoGRAMplusC4D 1000 Genomes-based 
GWAS (6) 
Proportion of MI cases minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.039 0.05 184,305 0.23 0.95 1.05 
COGNITION 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; (Lee et al) 
(7) 
 
β OLS* 
 
σ2 (x)** 
 
  σ2 (y) 
*** 
minimum beta to have 
>80% power 
0.039 0.05 257,841 0 2.25 1 0.250 
SBP 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; SBP 
automated (UK biobank) (8) 
 
β OLS* 
 
σ2 (x)** 
 
  σ2 (y) 
*** 
minimum beta to have 
>80% power 
0.039 0.05 473,891 0 2.25 1 0.193 
ALZHEIMER 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; IGAP 1st 
stage (9) 
Proportion of 
Alzheimer cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.039 0.05 54,162 0.31 0.91 1.10 
STROKE 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
MEGASTROKE (10) 
Proportion of any 
ischemic stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
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0.039 0.05 514,791 0.12 0.96 1.04 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
METASTROKE (10) 
Proportion of CES 
stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.039 0.05 514,791 0.02 0.90 1.13 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
METASTROKE (10) 
Proportion of LAS 
stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.039 0.05 514,791 0.013 0.88 1.12 
% of variance in urate 
explained by the 7 
SNPs 
 
Type-I error rate 
Sample size of the outcome dataset; 
METASTROKE (10) 
Proportion of SVS 
stroke cases 
minimum OR to 
have >80% power 
maximum OR to 
have >80% power 
0.039 0.05 514,791 0.023 0.90 1.10 
 
* the observational association estimate of the exposure-outcome relationship 
** variance of the exposure variable (x),  
*** variance of the outcome variable (y) 
CHD; coronary heart disease, MI; myocardial infraction, SBP; systolic blood pressure, CES; cardioembolic stroke, LAS; large vessels stroke, SVS; small vessels stroke 
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Table S5. The association estimates of the 28 SNPs for urate (1) with cognitive 
performance (7) 
 
  
SNP chr EA OA EAF GY SE_GY pval 
1 rs10480300 7 C T 0.704 -0.001 0.003 0.780 
2 rs10821905 10 A G 0.165 -0.001 0.004 0.856 
3 rs11264341 1 T C 0.412 0.000 0.003 0.878 
4 rs1165151 6 G T 0.551 -0.010 0.003 0.000 
5 rs1171614 10 T C 0.257 0.007 0.003 0.038 
6 rs1178977 7 G A 0.197 -0.007 0.004 0.047 
7 rs12498742 4 A G 0.779 -0.011 0.003 0.001 
8 rs1260326 2 C T 0.587 -0.003 0.003 0.237 
9 rs1394125 15 G A 0.645 -0.001 0.003 0.639 
10 rs1471633 1 C A 0.510 0.002 0.003 0.572 
11 rs17050272 2 G A 0.563 0.002 0.003 0.437 
12 rs17632159 5 G C 0.685 -0.003 0.003 0.389 
13 rs17786744 8 G A 0.439 0.003 0.003 0.348 
14 rs2078267 11 C T 0.442 0.003 0.003 0.249 
15 rs2231142 4 G T 0.893 0.001 0.005 0.886 
16 rs2941484 8 T C 0.422 -0.004 0.003 0.141 
17 rs3741414 12 T C 0.221 -0.010 0.003 0.002 
18 rs478607 11 G A 0.136 0.008 0.004 0.045 
19 rs653178 12 C T 0.473 -0.006 0.003 0.044 
20 rs6598541 15 G A 0.677 -0.004 0.003 0.197 
21 rs675209 6 C T 0.708 0.002 0.003 0.546 
22 rs6770152 3 G T 0.444 0.013 0.003 0.000 
23 rs7188445 16 A G 0.354 0.004 0.003 0.140 
24 rs7193778 16 T C 0.855 -0.009 0.004 0.032 
25 rs7224610 17 A C 0.585 0.004 0.003 0.136 
26 rs729761 6 T G 0.282 -0.006 0.003 0.054 
27 rs7953704 12 A G 0.481 0.003 0.003 0.272 
28 rs7976059 12 G T 0.645 0.006 0.003 0.050 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; EAF: effect 
allele frequency for GY; GY: beta for the SNP-cognition relationship; SE_GY: standard 
error of GY; pval: p-value of GY 
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Table S6. The association estimates of the 28 SNPs for urate (1) with Alzheimer's 
disease (9) 
 
  
SNP chr EA OA GY SE_GY pval 
1 rs10480300 7 T C 0.014 0.017 0.4349 
2 rs10821905 10 A G -0.025 0.021 0.2371 
3 rs11264341 1 T C 0.005 0.017 0.7549 
4 rs1165151 6 T G -0.004 0.016 0.8201 
5 rs1171614 10 T C -0.004 0.019 0.8503 
6 rs1178977 7 G A -0.011 0.021 0.6132 
7 rs12498742 4 G A 0.014 0.018 0.4517 
8 rs1260326 2 T C -0.001 0.016 0.9608 
9 rs1394125 15 A G 0.028 0.017 0.09825 
10 rs1471633 1 A C 0.029 0.016 0.07095 
11 rs17050272 2 A G 0.005 0.017 0.7625 
12 rs17632159 5 C G -0.012 0.017 0.4888 
13 rs17786744 8 G A 0.015 0.016 0.3461 
14 rs2078267 11 C T -0.022 0.016 0.1722 
15 rs2231142 4 T G 0.025 0.026 0.3347 
16 rs2941484 8 T C 0.011 0.016 0.4893 
17 rs3741414 12 T C 0.009 0.019 0.6299 
18 rs478607 11 G A 0.018 0.022 0.4173 
19 rs653178 12 C T 0.027 0.016 0.09708 
20 rs6598541 15 A G 0.005 0.016 0.7584 
21 rs675209 6 T C -0.011 0.018 0.5271 
22 rs6770152 3 G T 0.015 0.016 0.3378 
23 rs7188445 16 A G 0.016 0.017 0.3453 
24 rs7193778 16 C T -0.005 0.023 0.8233 
25 rs7224610 17 C A 0.018 0.016 0.2631 
26 rs729761 6 T G 0.020 0.019 0.2834 
27 rs7953704 12 A G 0.012 0.016 0.4454 
28 rs7976059 12 T G -0.031 0.017 0.07669 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; GY: beta for 
the SNP-Alzheimer's disease relationship; SE_GY: standard error of GY;  pval: p-
value of GY 
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Table S7. The association estimates of the 28 SNPs for urate (1) with coronary 
heart disease (CHD) (6) 
 
  
SNP chr EA OA EAF GY SE_GY pval 
1 rs10480300 7 C T 0.758 0.017 0.011 0.1365408 
2 rs10821905 10 G A 0.820 0.023 0.012 0.055396 
3 rs11264341 1 C T 0.568 -0.017 0.010 0.081745 
4 rs1165151 6 G T 0.539 -0.016 0.009 0.0815358 
5 rs1171614 10 C T 0.762 -0.012 0.012 0.3340968 
6 rs1178977 7 A G 0.823 0.006 0.013 0.6071614 
7 rs12498742 4 A G 0.767 0.012 0.011 0.2830966 
8 rs1260326 2 C T 0.610 -0.003 0.010 0.7349392 
9 rs1394125 15 G A 0.691 -0.006 0.011 0.5658209 
10 rs1471633 1 A C 0.537 0.017 0.010 0.0749271 
11 rs17050272 2 G A 0.597 -0.006 0.010 0.5597656 
12 rs17632159 5 G C 0.691 -0.003 0.010 0.7899725 
13 rs17786744 8 A G 0.630 -0.005 0.010 0.6015566 
14 rs2078267 11 C T 0.540 0.001 0.010 0.9107651 
15 rs2231142 4 G T 0.887 0.024 0.015 0.1143624 
16 rs2941484 8 C T 0.563 -0.010 0.009 0.2861924 
17 rs3741414 12 C T 0.799 -0.012 0.012 0.3185743 
18 rs478607 11 A G 0.810 0.005 0.013 0.668657 
19 rs653178 12 T C 0.579 -0.064 0.010 5.15E-10 
20 rs6598541 15 G A 0.598 0.006 0.009 0.5183619 
21 rs675209 6 C T 0.645 0.016 0.010 0.1229597 
22 rs6770152 3 T G 0.573 -0.019 0.009 0.0409614 
23 rs7188445 16 G A 0.705 0.007 0.011 0.515785 
24 rs7193778 16 T C 0.836 -0.009 0.014 0.4928628 
25 rs7224610 17 A C 0.607 0.006 0.010 0.5373028 
26 rs729761 6 G T 0.718 -0.013 0.011 0.2615705 
27 rs7953704 12 G A 0.527 -0.009 0.009 0.3281571 
28 rs7976059 12 G T 0.632 0.004 0.010 0.6806164 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; EAF: effect 
allele frequency for GY; GY: beta for the SNP-CHD relationship; SE_GY: standard 
error of GY; pval: p-value of GY 
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Table S8. The association estimates of the 28 SNPs for urate (1) with myocardial 
infarction (MI) (6) 
 
  
SNP chr EA OA EAF GY SE_GY pval 
1 rs10480300 7 T C 0.245 0.010 0.013 0.41820349 
2 rs10821905 10 A G 0.176 0.035 0.013 0.00932379 
3 rs11264341 1 T C 0.421 -0.016 0.011 0.13180104 
4 rs1165151 6 G T 0.533 -0.023 0.010 0.02632004 
5 rs1171614 10 C T 0.742 -0.002 0.014 0.87910941 
6 rs1178977 7 G A 0.172 0.007 0.014 0.63826783 
7 rs12498742 4 G A 0.228 0.013 0.012 0.29664083 
8 rs1260326 2 T C 0.422 -0.001 0.011 0.9166279 
9 rs1394125 15 A G 0.299 -0.002 0.012 0.88583215 
10 rs1471633 1 C A 0.452 0.016 0.011 0.13190286 
11 rs17050272 2 A G 0.378 0.005 0.011 0.64781176 
12 rs17632159 5 C G 0.298 -0.007 0.011 0.51468404 
13 rs17786744 8 G A 0.369 -0.005 0.011 0.65350967 
14 rs2078267 11 T C 0.438 -0.008 0.011 0.47673314 
15 rs2231142 4 T G 0.110 0.022 0.017 0.19174707 
16 rs2941484 8 T C 0.430 -0.018 0.010 0.07495691 
17 rs3741414 12 T C 0.193 0.003 0.014 0.82049052 
18 rs478607 11 A G 0.776 0.004 0.014 0.78504645 
19 rs653178 12 T C 0.558 -0.077 0.012 2.84E-11 
20 rs6598541 15 G A 0.580 0.010 0.011 0.35000693 
21 rs675209 6 C T 0.627 0.018 0.011 0.10676248 
22 rs6770152 3 T G 0.559 -0.017 0.010 0.11390205 
23 rs7188445 16 A G 0.291 0.005 0.012 0.65739895 
24 rs7193778 16 T C 0.811 0.003 0.015 0.83535075 
25 rs7224610 17 A C 0.587 0.003 0.011 0.78176886 
26 rs729761 6 G T 0.696 -0.018 0.012 0.14330225 
27 rs7953704 12 G A 0.513 -0.019 0.010 0.0648285 
28 rs7976059 12 T G 0.357 0.006 0.011 0.55745239 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; EAF: 
effect allele frequency for GY; GY: beta for the SNP-MI relationship; SE_GY: 
standard error of GY; pval: p-value of GY 
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Table S9. The association estimates of the 28 SNPs for urate (1) with systolic 
blood pressure (SBP) (8) 
 
  
SNP chr EA OA GY SE_GY pval 
1 rs10480300 7 T C 0.015 0.003 1.45E-07 
2 rs10821905 10 A G 0.009 0.003 0.00435053 
3 rs11264341 1 T C -0.008 0.002 0.00082043 
4 rs1165151 6 G T -0.006 0.002 0.00999244 
5 rs1171614 10 C T -0.008 0.003 0.00897198 
6 rs1178977 7 G A 0.001 0.003 0.676104 
7 rs12498742 4 G A 0.004 0.003 0.21947 
8 rs1260326 2 C T 0.005 0.003 0.0439014 
9 rs1394125 15 A G 0.002 0.003 0.47681 
10 rs1471633 1 C A 0.002 0.002 0.313305 
11 rs17050272 2 A G 0.002 0.002 0.353964 
12 rs17632159 5 C G 0.003 0.003 0.348555 
13 rs17786744 8 G A 0.004 0.003 0.158785 
14 rs2078267 11 T C 0.000 0.002 0.998987 
15 rs2231142 4 T G -0.011 0.004 0.00493599 
16 rs2941484 8 T C 0.008 0.002 0.00218681 
17 rs3741414 12 T C -0.009 0.003 0.00195694 
18 rs478607 11 A G -0.005 0.003 0.136448 
19 rs653178 12 T C -0.021 0.002 1.16E-17 
20 rs6598541 15 G A -0.001 0.003 0.618474 
21 rs675209 6 C T -0.001 0.003 0.592666 
22 rs6770152 3 T G -0.006 0.002 0.0220286 
23 rs7188445 16 A G 0.001 0.003 0.654585 
24 rs7193778 16 T C -0.016 0.003 2.19E-06 
25 rs7224610 17 A C -0.008 0.003 0.0024854 
26 rs729761 6 G T 0.002 0.003 0.506385 
27 rs7953704 12 G A -0.004 0.002 0.124599 
28 rs7976059 12 T G 0.005 0.003 0.048739 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; GY: beta 
for the SNP-SBP relationship; SE_GY: standard error of GY; pval: p-value of GY 
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Table S10.The association estimates of the 28 SNPs for urate (1) with any 
ischemic stroke (IS) (10) 
 
  
SNP chr EA OA EAF GY SE_GY pval 
1 rs10480300 7 T C 0.268 0.015 0.010 0.1382 
2 rs10821905 10 A G 0.193 -0.007 0.011 0.5244 
3 rs11264341 1 T C 0.468 -0.007 0.009 0.4156 
4 rs1165151 6 T G 0.432 -0.012 0.009 0.1708 
5 rs1171614 10 T C 0.226 -0.003 0.012 0.7939 
6 rs1178977 7 A G 0.811 0.008 0.012 0.5083 
7 rs12498742 4 A G 0.728 -0.010 0.011 0.366 
8 rs1260326 2 T C 0.414 0.006 0.009 0.5155 
9 rs1394125 15 A G 0.333 0.010 0.010 0.2888 
10 rs1471633 1 A C 0.537 0.007 0.010 0.4749 
11 rs17050272 2 A G 0.424 -0.010 0.009 0.2692 
12 rs17632159 5 C G 0.302 0.008 0.009 0.3547 
13 rs17786744 8 A G 0.624 -0.008 0.009 0.3781 
14 rs2078267 11 T C 0.491 0.021 0.010 0.03 
15 rs2231142 4 T G 0.175 -0.003 0.013 0.8286 
16 rs2941484 8 T C 0.454 -0.007 0.009 0.4401 
17 rs3741414 12 T C 0.227 -0.002 0.011 0.8872 
18 rs478607 11 A G 0.787 -0.017 0.011 0.1007 
19 rs653178 12 T C 0.543 -0.077 0.010 4.31E-14 
20 rs6598541 15 A G 0.409 0.011 0.009 0.1887 
21 rs675209 6 T C 0.346 -0.014 0.010 0.153 
22 rs6770152 3 T G 0.566 0.012 0.009 0.1693 
23 rs7188445 16 A G 0.312 -0.002 0.009 0.8374 
24 rs7193778 16 T C 0.861 -0.009 0.012 0.4761 
25 rs7224610 17 A C 0.631 0.002 0.009 0.8432 
26 rs729761 6 T G 0.247 -0.014 0.011 0.1802 
27 rs7953704 12 A G 0.487 -0.023 0.008 0.005882 
28 rs7976059 12 T G 0.414 -0.010 0.009 0.2491 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; EAF: 
effect allele frequency for GY; GY: beta for the SNP-IS relationship; SE_GY: 
standard error of GY; pval: p-value of GY 
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Table S11. The association estimates of the 28 SNPs for urate (1) with cardio-
embolic stroke (CES) (10) 
 
  
SNP chr EA OA EAF GY SE_GY pval 
1 rs10480300 7 T C 0.268 0.006 0.020 0.7797 
2 rs10821905 10 A G 0.194 0.022 0.023 0.3331 
3 rs11264341 1 T C 0.447 -0.034 0.017 0.05135 
4 rs1165151 6 T G 0.456 0.006 0.018 0.74 
5 rs1171614 10 T C 0.227 0.011 0.023 0.6229 
6 rs1178977 7 A G 0.814 0.014 0.024 0.5559 
7 rs12498742 4 A G 0.744 -0.019 0.021 0.3559 
8 rs1260326 2 T C 0.407 -0.013 0.019 0.4791 
9 rs1394125 15 A G 0.343 -0.006 0.020 0.7566 
10 rs1471633 1 A C 0.513 -0.005 0.018 0.7993 
11 rs17050272 2 A G 0.421 -0.007 0.018 0.6876 
12 rs17632159 5 C G 0.307 0.021 0.019 0.2671 
13 rs17786744 8 A G 0.612 0.007 0.018 0.7048 
14 rs2078267 11 T C 0.500 0.029 0.018 0.1192 
15 rs2231142 4 T G 0.147 0.002 0.028 0.9473 
16 rs2941484 8 T C 0.446 -0.002 0.017 0.9104 
17 rs3741414 12 T C 0.235 0.005 0.022 0.8014 
18 rs478607 11 A G 0.809 0.025 0.024 0.2943 
19 rs653178 12 T C 0.541 -0.058 0.020 0.003023 
20 rs6598541 15 A G 0.393 0.038 0.017 0.02562 
21 rs675209 6 T C 0.321 -0.013 0.021 0.513 
22 rs6770152 3 T G 0.572 -0.003 0.017 0.8761 
23 rs7188445 16 A G 0.315 -0.016 0.018 0.3768 
24 rs7193778 16 T C 0.858 -0.003 0.025 0.9134 
25 rs7224610 17 A C 0.610 0.011 0.018 0.5317 
26 rs729761 6 T G 0.258 0.008 0.022 0.7082 
27 rs7953704 12 A G 0.487 -0.024 0.017 0.1624 
28 rs7976059 12 T G 0.387 -0.015 0.018 0.4187 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; EAF: effect 
allele frequency for GY; GY: beta for the SNP-CE relationship; SE_GY: standard error 
of GY; pval: p-value of GY 
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Table S12. The association estimates of the 28 SNPs for urate (1) with large-
artery atherosclerotic stroke (LAS) (10) 
 
  
SNP chr EA OA EAF GY SE_GY pval 
1 rs10480300 7 T C 0.269 0.030 0.026 0.2486 
2 rs10821905 10 A G 0.183 0.015 0.028 0.6083 
3 rs11264341 1 T C 0.484 -0.032 0.021 0.1239 
4 rs1165151 6 T G 0.426 -0.032 0.022 0.1419 
5 rs1171614 10 T C 0.227 0.038 0.029 0.1838 
6 rs1178977 7 A G 0.823 0.023 0.028 0.4106 
7 rs12498742 4 A G 0.740 -0.027 0.026 0.3058 
8 rs1260326 2 T C 0.436 0.012 0.022 0.5781 
9 rs1394125 15 A G 0.324 0.045 0.024 0.06338 
10 rs1471633 1 A C 0.546 0.008 0.023 0.7251 
11 rs17050272 2 A G 0.431 -0.024 0.021 0.2399 
12 rs17632159 5 C G 0.304 0.011 0.022 0.6205 
13 rs17786744 8 A G 0.635 0.001 0.021 0.9619 
14 rs2078267 11 T C 0.496 0.028 0.024 0.2299 
15 rs2231142 4 T G 0.192 -0.008 0.029 0.7724 
16 rs2941484 8 T C 0.447 -0.001 0.020 0.9471 
17 rs3741414 12 T C 0.216 -0.009 0.027 0.7512 
18 rs478607 11 A G 0.799 -0.046 0.027 0.08713 
19 rs653178 12 T C 0.534 -0.094 0.026 0.000238 
20 rs6598541 15 A G 0.414 0.017 0.020 0.3917 
21 rs675209 6 T C 0.364 -0.025 0.025 0.3254 
22 rs6770152 3 T G 0.553 0.014 0.020 0.501 
23 rs7188445 16 A G 0.313 0.044 0.022 0.04303 
24 rs7193778 16 T C 0.862 -0.081 0.029 0.005975 
25 rs7224610 17 A C 0.639 0.025 0.022 0.2496 
26 rs729761 6 T G 0.244 -0.024 0.026 0.3675 
27 rs7953704 12 A G 0.490 -0.041 0.020 0.03757 
28 rs7976059 12 T G 0.437 0.016 0.021 0.4463 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; EAF: effect 
allele frequency for GY; GY: beta for the SNP-LAS relationship; SE_GY: standard 
error of GY; pval: p-value of GY 
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Table S13. The association estimates of the 28 SNPs for urate (1) with small-
vessel stroke (SVS) (10) 
 
  
SNP chr EA OA EAF GY SE_GY pval 
1 rs10480300 7 T C 0.265 -0.021 0.024 0.3765 
2 rs10821905 10 A G 0.178 -0.017 0.025 0.489 
3 rs11264341 1 T C 0.521 0.014 0.017 0.4048 
4 rs1165151 6 T G 0.388 -0.041 0.019 0.03197 
5 rs1171614 10 T C 0.228 -0.004 0.026 0.8896 
6 rs1178977 7 A G 0.822 0.011 0.023 0.6485 
7 rs12498742 4 A G 0.721 0.018 0.024 0.4411 
8 rs1260326 2 T C 0.453 0.021 0.018 0.2346 
9 rs1394125 15 A G 0.304 -0.032 0.021 0.126 
10 rs1471633 1 A C 0.578 0.007 0.020 0.7272 
11 rs17050272 2 A G 0.436 -0.031 0.017 0.07663 
12 rs17632159 5 C G 0.297 0.042 0.018 0.02171 
13 rs17786744 8 A G 0.653 0.010 0.018 0.5885 
14 rs2078267 11 T C 0.486 0.020 0.022 0.3554 
15 rs2231142 4 T G 0.219 0.005 0.023 0.8172 
16 rs2941484 8 T C 0.452 -0.008 0.017 0.6376 
17 rs3741414 12 T C 0.204 0.021 0.023 0.3575 
18 rs478607 11 A G 0.771 -0.035 0.021 0.09941 
19 rs653178 12 T C 0.544 -0.104 0.023 8.42E-06 
20 rs6598541 15 A G 0.434 0.004 0.017 0.7922 
21 rs675209 6 T C 0.408 -0.014 0.022 0.5217 
22 rs6770152 3 T G 0.539 0.013 0.017 0.4429 
23 rs7188445 16 A G 0.309 0.004 0.018 0.8338 
24 rs7193778 16 T C 0.865 -0.016 0.025 0.5174 
25 rs7224610 17 A C 0.669 -0.007 0.019 0.7091 
26 rs729761 6 T G 0.226 -0.055 0.022 0.01285 
27 rs7953704 12 A G 0.491 -0.008 0.016 0.6139 
28 rs7976059 12 T G 0.483 -0.023 0.018 0.1978 
 
SNP: each SNP's id; chr: chromosome; EA: effect allele, OA: other allele; EAF: effect 
allele frequency for GY; GY: beta for the SNP-SVS relationship; SE_GY: standard 
error of GY; pval: p-value of GY 
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Figure S1. Forest plot of the 28 MR estimates of the urate-cognitive performance 
relationship.  
 
 
 
 
 
Each dot indicates the effect estimate of each SNP with horizontal lines represent the 
95% confidence interval (CI) of this estimate. 
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Figure S2. Forest plot of the 28 MR estimates of the urate-Alzheimer’s disease 
relationship. 
 
 
 
 
 
Each dot indicates the effect estimate (logOR) of each SNP with horizontal lines 
represent the 95% confidence interval (CI) of this estimate. 
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Figure S3. Forest plot of the 28 MR estimates of the urate-coronary heart disease 
(CHD) relationship. 
 
 
 
 
 
Each dot indicates the effect estimate (logOR) of each SNP with horizontal lines 
represent the 95% confidence interval (CI) of this estimate. 
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Figure S4. Forest plot of the 28 MR estimates of the urate-myocardial infarction 
(MI) relationship. 
 
 
 
 
 
 
  
Each dot indicates the effect estimate (logOR) of each SNP with horizontal lines 
represent the 95% confidence interval (CI) of this estimate. 
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Figure S5. Forest plot of the 28 MR estimates of the urate-systolic blood 
pressure (SBP) relationship. 
 
 
 
 
 
Each dot indicates the effect estimate of each SNP with horizontal lines represent the 
95% confidence interval (CI) of this estimate. 
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Figure S6. Forest plot of the 28 MR estimates of the urate- any ischemic stroke 
relationship. 
 
 
 
 
 
Each dot indicates the effect estimate (logOR) of each SNP with horizontal lines 
represent the 95% confidence interval (CI) of this estimate. 
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Figure S7. Forest plot of the 28 MR estimates of the urate- cardioembolic stroke 
ischemic stroke (CES) relationship.  
 
 
 
 
 
Each dot indicates the effect estimate (logOR) of each SNP with horizontal lines 
represent the 95% confidence interval (CI) of this estimate. 
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Figure S8. Forest plot of the 28 MR estimates of the urate- large-artery 
atherosclerotic ischemic stroke (LAS) relationship. 
 
 
 
 
 
Each dot indicates the effect estimate (logOR) of each SNP with horizontal lines 
represent the 95% confidence interval (CI) of this estimate. 
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Figure S9. Forest plot of the 28 MR estimates of the urate- small-artery stroke 
ischemic stroke (SAS) relationship. 
 
 
 
 
 
Each dot indicates the effect estimate (logOR) of each SNP with horizontal lines 
represent the 95% confidence interval (CI) of this estimate. 
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Figure S10. Funnel plot (A) and radial plot (B) for the urate-cognitive performance relationship. 
 
(A)                                                                                                            (B) 
 
  
D
ow
nloaded from
 http://ahajournals.org by on September 2, 2019
 
Figure S11. Funnel plot (A) and radial plot (B) for the urate-Alzheimer’s disease relationship. 
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Figure S12. Funnel plot (A) and radial plot (B) for the urate-coronary heart disease (CHD) relationship.  
 
 
(A)                                                                                                            (B) 
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Figure S13. Funnel plot (A) and radial plot (B) for the urate-myocardial infarction (MI) relationship.  
 
 
(A)                                                                                                            (B) 
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Figure S14. Funnel plot (A) and radial plot (B) for the urate- systolic blood pressure (SBP) relationship.  
 
 
 
(A)                                                                                                            (B) 
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Figure S15. Funnel plot (A) and radial plot (B) for the urate-any ischemic stroke relationship. 
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Figure S16. Funnel plot (A) and radial plot (B) for the urate- cardioembolic ischemic stroke (CES) relationship.  
 
 
(A)                                                                                                            (B) 
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Figure S17. Funnel plot (A) and radial plot (B) for the urate- large-artery atherosclerotic ischemic stroke (LAS) relationship. 
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Figure S18. Funnel plot (A) and radial plot (B) for the urate- small-artery ischemic stroke (SVS) relationship. 
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Figure S19. Forest plot for the association of uric acid with cognitive 
performance.  
 
 
 
 
 
 
 
 
 
 
All methods performed in this study are included. Each box indicates the effect 
estimate (beta) calculated by each method with horizontal lines represent the 95% 
confidence interval (CI) of this estimate.  
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Figure S20. Forest plot for the association of uric acid with Alzheimer’s disease.   
 
 
 
 
 
 
 
 
 
 
All methods performed in this study are included. Each box indicates the effect 
estimate (odds ratio [OR]) calculated by each method with horizontal lines represent 
the 95% confidence interval (CI) of this estimate.  
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Figure S21. Forest plots for the association of uric acid with coronary heart 
disease (CHD), myocardial infarction (MI).  
 
 
 
 
 
 
 
 
 
 
All methods performed in this study are included. Each box indicates the effect 
estimate (odds ratio [OR]) calculated by each method with horizontal lines represent 
the 95% confidence interval (CI) of this estimate.  
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Figure S22. Forest plot for the association of uric acid with systolic blood 
pressure (SBP). 
 
 
 
 
 
 
 
 
 
 
All methods performed in this study are included. Each box indicates the effect 
estimate (beta) calculated by each method with horizontal lines represent the 95% 
confidence interval (CI) of this estimate.  
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Figure S23. Forest plots for the association of uric acid with ischemic stroke 
(any type) and its subtypes (cardioembolic stroke [CES], stroke caused by 
small-vessel disease (small-vessel stroke [SVS] and large-artery atherosclerotic 
stroke [LAS]). 
 
 
 
 
 
All methods performed in this study are included. Each box indicates the effect 
estimate (odds ratio [OR]) calculated by each method with horizontal lines represent 
the 95% confidence interval (CI) of this estimate.
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